These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17635574)

  • 1. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia.
    Karpisek M; Stejskal D; Kotolova H; Kollar P; Janoutova G; Ochmanova R; Cizek L; Horakova D; Yahia RB; Lichnovska R; Janout V
    Eur J Clin Invest; 2007 Aug; 37(8):637-42. PubMed ID: 17635574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study.
    Xu A; Tso AW; Cheung BM; Wang Y; Wat NM; Fong CH; Yeung DC; Janus ED; Sham PC; Lam KS
    Circulation; 2007 Mar; 115(12):1537-43. PubMed ID: 17389279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
    Holmberg B; Brännström M; Bucht B; Crougneau V; Dimeny E; Ekspong A; Granroth B; Gröntoft KC; Hadimeri H; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Welin D; Wikdahl AM; Stegmayr BG
    Scand J Urol Nephrol; 2005; 39(6):503-10. PubMed ID: 16303728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients.
    Tsouchnikas I; Dounousi E; Papakonstantinou S; Ioannou K; Kelesidis A; Kotzadamis N; Xanthopoulou K; Tsakiris D
    Nephrology (Carlton); 2009 Sep; 14(6):560-4. PubMed ID: 19422526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of atorvastatin on serum lipoproteins in acromegaly.
    Mishra M; Durrington P; Mackness M; Siddals KW; Kaushal K; Davies R; Gibson M; Ray DW
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):650-5. PubMed ID: 15943824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
    Kosmidou MS; Hatzitolios AI; Adamidou A; Giannopoulos S; Raikos N; Parharidis G; Milionis HJ
    Am J Hypertens; 2008 Mar; 21(3):303-9. PubMed ID: 18202666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S; Geiss HC; Otto C; Parhofer KG
    Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
    Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
    Boonbaichaiyapruck S; Cheepudomwit S; Panjavenin P; Suthichaiyakul T; Moleelerkpoom W; Benjanuwatra T; Sukanandachai B; Buakhamsri A
    J Med Assoc Thai; 2008 Aug; 91(8):1189-95. PubMed ID: 18788689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
    Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating adipocyte fatty acid binding protein levels in healthy preterm infants: Positive correlation with weight gain and total-cholesterol levels.
    Siahanidou T; Margeli A; Davradou M; Apostolakou F; Papassotiriou I; Roma E; Mandyla H; Chrousos G
    Early Hum Dev; 2010 Apr; 86(4):197-201. PubMed ID: 20231079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between adipocyte fatty acid-binding protein levels and childhood obesity in Korean children.
    Yun KE; Kim SM; Choi KM; Park HS
    Metabolism; 2009 Jun; 58(6):798-802. PubMed ID: 19368945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.